Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 29 results found since Jan 2013.
Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab —A Case Report
Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2017 Category: Neurology Authors: Derya Tireli, Jun He, Mette Maria Nordling, Troels Wienecke Tags: Case Studies Source Type: research
Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience
Intravenous thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) using oral anticoagulants. A specific human monoclonal antibody was introduced to reverse immediately the anticoagulation effect of the direct inhibitor of thrombin, dabigatran. Until now, mostly individual cases presenting with successful IVT after a reversal of dabigatran anticoagulation in patients with AIS were published. Thus, we aimed to report real-world data from clinical practice.
Source: Journal of Stroke and Cerebrovascular Diseases - May 25, 2018 Category: Neurology Authors: Daniel Šaňák, Stanislava Jakubíček, David Černík, Roman Herzig, Zdeněk Kunáš, Robert Mikulík, Svatopluk Ostrý, Michal Reif, Vladimír Rohan, Aleš Tomek, Tomáš Veverka Source Type: research
Dabigatran Plasma Levels in Acute Cerebrovascular Events
Oral anticoagulation with dabigatran was shown to be effective for stroke prevention in patients with nonvalvular atrial fibrillation without the need for laboratory monitoring. However, a recent publication based on data of the Randomized Evaluation of Long-Term Anticoagulation Therapy study reported that ischemic stroke and bleeding outcomes are correlated with dabigatran plasma concentration (DPC). DPC was determined at a prespecified time point and correlated with cardiovascular events at any time during follow-up.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2016 Category: Neurology Authors: Bastian Volbers, Martin Köhrmann, Bernd Kallmünzer, Natalia Kurka, Lorenz Breuer, Jürgen Ringwald, Stefan Schwab Source Type: research
Recurrent Ischemic Stroke in a Patient with the Trousseau Syndrome Treated with Dabigatran
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Kosuke Yoshida, Takashi Kimura, Yoko Aburakawa, Yasuhiro Suzuki, Kenji Kuroda, Osamu Yahara Tags: Case Reports Source Type: research
Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2014 Category: Neurology Authors: Mahesh Kate, Artur Szkotak, Adam Witt, Ashfaq Shuaib, Kenneth Butcher Tags: Original Articles Source Type: research
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report
We present a case of immune hemolytic anemia (IHA) due to dabigatran use in a 72-year-old male with NVAF.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2020 Category: Neurology Authors: Jin-Hong Gong, Guang-Jun Liu, Feng Zhou, Zhi-Qiang Sun Tags: Case Report Source Type: research
Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Major hemorrhagic complication incidence in patients with arterial fibrillation (AF), and treated with direct oral anticoagulants (DOACs), is lower than in vitamin K antagonist-treated patients.1 –5 Additionally, among DOACs, the direct oral thrombin inhibitor (dabigatran) and direct oral factor Xa (FXa) inhibitors (apixaban and rivaroxaban) seem to affect the coagulation system differently, which could provide distinct clinical outcomes.6,7 The results from the US6 and Denmark8 cohort stu dies suggest there is a minute, but notable difference in major bleeding complication incidence between dabigatran and FXa inhibitors.
Source: Journal of Stroke and Cerebrovascular Diseases - May 3, 2022 Category: Neurology Authors: Masahito Nakazaki, Shinichi Oka, Hirotoshi Magota, Ryo Kiyose, Rie Onodera, Ryo Ukai, Yuko Kataoka-Sasaki, Masanori Sasaki, Osamu Honmou Source Type: research
Dabigatran-related Intracerebral Hemorrhage Resulting in Hematoma Expansion
We present a case that suggests that hematoma expansion may occur after NOAC-related ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Claus Z. Simonsen, Thorsten Steiner, Anna Tietze, Dorte Damgaard Tags: Case Reports Source Type: research
Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research
Does Dabigatran Increase the Risk of Delayed Hematoma Expansion in a Rat Model of Collagenase-Induced Intracerebral Hemorrhage?
This study aims to clarify whether dabigatran increases the risk of delayed hematoma expansion in a rat ICH model.
Source: Journal of Stroke and Cerebrovascular Diseases - November 25, 2014 Category: Neurology Authors: Shunsuke Tanoue, Joji Inamasu, Masayuki Yamada, Hiroshi Toyama, Yuichi Hirose Source Type: research
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients —Analysis of Pharmaceuticals and Medical Devices Agency Data
Two forms of direct oral anticoagulant (DOAC) have recently been introduced: direct thrombin inhibitors (DTI; e.g., dabigatran) and factor Xa inhibitors (FXa; e.g., rivaroxaban and apixaban). Despite the advantages of DOACs over warfarin with regard to cerebrovascular complications, those associated with DOACs have been reported with the increasing use of DOACs. Nevertheless, little is known about real-world comparative efficacy and safety of DOACs.
Source: Journal of Stroke and Cerebrovascular Diseases - February 3, 2017 Category: Neurology Authors: Yasuo Terayama Source Type: research
Severe Vasospasm of the Middle Cerebral Artery after Mechanical Thrombectomy Due to Infective Endocarditis: An Autopsy Case
We describe a case of middle cerebral artery occlusion due to IE, which caused severe vasospasm and reocclusion after mechanical thrombectomy (MT). We present the pathologic findings of the occluded middle cerebral artery and investigate the precautions to be taken while performing MT due to IE. A 72-year-old man with atrial fibrillation treated with dabigatran presented with right hemiparesis and aphasia.
Source: Journal of Stroke and Cerebrovascular Diseases - June 29, 2017 Category: Neurology Authors: Wataru Nishino, Yosuke Tajima, Toru Inoue, Michihiro Hayasaka, Bi Katsu, Koichi Ebihara, Daisuke Kawauchi, Masaaki Kubota, Sumio Suda Tags: Case Studies Source Type: research
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
This study aims to observe the effectiveness and safety of idarucizumab in dabigatran-treated patients with severe bleeding or requiring surgery in Taiwan.
Source: Journal of Stroke and Cerebrovascular Diseases - November 6, 2017 Category: Neurology Authors: Li-Kai Tsai, Huey-Juan Lin, Su-Kiat Chua, Pen-Chih Liao, Yuan-Po Yang, Ping-Chen Chou, Chun-Wei Lee, Mao-Jen Lin, Hsi-Ming Chen, Jung-Tze Yeh, Yi-Heng Li Tags: Case Studies Source Type: research
Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity
The plasminogen activator inhibitor-1 (PAI-1) 4G/4G homozygous genotype represents a genetic thrombophilia that has been associated with enhanced risk of arterial and venous thrombotic events. The optimal anticoagulation strategy for PAI-1 4G homozygous patients is unclear. Herein we present a case of a patient with PAI-1 4G/4G homozygosity who was placed on dabigatran after developing cerebral venous sinus thrombosis (CVST), but who then suffered an acute myocardial infarction several weeks later.
Source: Journal of Stroke and Cerebrovascular Diseases - August 25, 2020 Category: Neurology Authors: Daniel Chiu, Jesse Weinberger Tags: Case Report Source Type: research
